| Literature DB >> 12142080 |
A Ladopoulou1, C Kroupis, I Konstantopoulou, L Ioannidou-Mouzaka, A C Schofield, A Pantazidis, S Armaou, I Tsiagas, E Lianidou, E Efstathiou, C Tsionou, C Panopoulos, M Mihalatos, G Nasioulas, D Skarlos, N E Haites, G Fountzilas, N Pandis, D Yannoukakos.
Abstract
BRCA1 and BRCA2 genes were screened for loss-of-function mutations in a series of 85 patients having at least one first- or second-degree relative affected by breast and/or ovarian cancer. All BRCA1 exons and BRCA2 exons 10 and 11 were screened with a combination of methods including SSCP, PTT and direct sequencing. We have found disease-associated mutations in 14 families (16.5%), eleven in BRCA1 and three in BRCA2. The known founder mutation 5382insC of BRCA1 was identified in seven unrelated families. The other mutations identified include the non-sense R1751X, the splice junction variant 5586G>A of BRCA1 and three frameshifts, 2024del5, 3034del4, and 6631del5, of BRCA2. Nine out of these 14 families had a family history of three or more breast/ovarian cancer cases. A large number of polymorphic or unclassified variants is also reported. Combined with our previously published data 5382insC was found in nine out of 20 families (45%), suggesting that this mutation may represent a common founder mutation in the Greek population.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12142080 DOI: 10.1016/s0304-3835(01)00845-x
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679